Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hoth Therapeutics ( (HOTH) ) has shared an announcement.
On June 18, 2025, Hoth Therapeutics announced it regained compliance with Nasdaq’s minimum bid price requirement, a significant milestone that reflects growing market confidence in its strategy and pipeline. This achievement allows Hoth to focus on advancing its clinical portfolio across multiple therapeutic areas, positioning the company for significant value creation in 2025.
The most recent analyst rating on (HOTH) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Hoth Therapeutics stock, see the HOTH Stock Forecast page.
More about Hoth Therapeutics
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. Their pipeline includes treatments targeting rare diseases, inflammatory skin disorders, cancer, and neurological conditions.
Average Trading Volume: 1,168,950
Technical Sentiment Signal: Buy
Current Market Cap: $17.7M
Find detailed analytics on HOTH stock on TipRanks’ Stock Analysis page.